Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

Daniel Stanzione net worth and biography

Daniel Stanzione Biography and Net Worth

Director of Quest Diagnostics

Dr. Daniel C. Stanzione Ph.D. serves as Lead Independent Director of the Company. Dr. Stanzione retired from Lucent Technologies Incorporated in 2000 and is President Emeritus of Bell Laboratories and an independent consultant. Dr. Stanzione began his career in 1972 with Bell Laboratories, where he led the teams working on the first microprocessors and digital signal processors. He was appointed President of Network Systems, Lucent’s largest business unit, in 1996 and was appointed Chief Operating Officer of Lucent in 1997. Dr. Stanzione served as a director of Internap Corporation from 2005 to 2018 and served as a director of Avaya Inc. from 2000 until 2007. He has served on the boards of a number of private companies and currently is a director of Catheter Precision, Inc. Dr. Stanzione has been Lead Independent Director since January 1, 2017 and served as Chairman from May 1, 2012 until January 1, 2017.

What is Daniel Stanzione's net worth?: The estimated net worth of Daniel Stanzione is at least $5.20 million as of November 23rd, 2020. Stanzione owns 33,951 shares of Quest Diagnostics stock worth more than $5,197,898 as of December 22nd. This net worth approximation does not reflect any other assets that Stanzione may own. Learn More about Daniel Stanzione's net worth.
How do I contact Daniel Stanzione?: The corporate mailing address for Stanzione and other Quest Diagnostics executives is 500 PLAZA DRIVE, SECAUCUS NJ, 07094. Quest Diagnostics can also be reached via phone at (973) 520-2700 and via email at [email protected]. Learn More on Daniel Stanzione's contact information.
Has Daniel Stanzione been buying or selling shares of Quest Diagnostics?: Daniel Stanzione has not been actively trading shares of Quest Diagnostics during the past quarter. Most recently, Daniel Stanzione sold 11,223 shares of the business's stock in a transaction on Monday, November 23rd. The shares were sold at an average price of $126.30, for a transaction totalling $1,417,464.90. Following the completion of the sale, the director now directly owns 33,951 shares of the company's stock, valued at $4,288,011.30. Learn More on Daniel Stanzione's trading history.
Who are Quest Diagnostics' active insiders?: Quest Diagnostics' insider roster includes Mark Delaney (SVP), Michael Deppe (CAO), Catherine Doherty (SVP), Vicky Gregg (Director), Mark Guinan (CFO), Karthik Kuppusamy (SVP), Michael Prevoznik (SVP), Timothy Ring (Director), Stephen Rusckowski (CEO), Daniel Stanzione (Director), and Gail Wilensky (Director). Learn More on Quest Diagnostics' active insiders.
Are insiders buying or selling shares of Quest Diagnostics?: In the last twelve months, insiders at the medical research company sold shares 10 times. They sold a total of 39,850 shares worth more than $5,692,423.40. The most recent insider tranaction occured on November, 6th when CAO Michael J Deppe sold 18,755 shares worth more than $2,889,207.75. Insiders at Quest Diagnostics own 0.8% of the company. Learn More about insider trades at Quest Diagnostics.
Information on this page was last updated on 11/6/2024.

Daniel Stanzione Insider Trading History at Quest Diagnostics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/23/2020	Sell	11,223	$126.30	$1,417,464.90	33,951
9/11/2017	Sell	40,900	$108.07	$4,420,063.00	41,991
9/5/2017	Sell	3,803	$108.01	$410,762.03	35,359
2/11/2015	Sell	8,000	$70.97	$567,760.00

Daniel Stanzione Buying and Selling Activity at Quest Diagnostics

Quest Diagnostics Company Overview

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Today's Range

Now: $153.10

$151.68

$154.10

50 Day Range

MA: $157.03

$147.40

$164.19

2 Week Range

Now: $153.10

$123.04

$165.32

Volume

1,344,317 shs

Average Volume

917,121 shs

Market Capitalization

$17.09 billion

P/E Ratio

20.58

Dividend Yield

1.98%

Beta

0.89